Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers befo...

Full description

Saved in:
Bibliographic Details
Published in:Scientific Reports Vol. 12; no. 1; pp. 193 - 9
Main Authors: Yoo, Hae Won, Park, Jun Yong, Kim, Sang Gyune, Jung, Young Kul, Lee, Sae Hwan, Kim, Moon Young, Jun, Dae Won, Jang, Jae Young, Lee, Jin Woo, Kwon, Oh Sang
Format: Journal Article
Language:English
Published: London Springer Science and Business Media LLC 07.01.2022
Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Subjects:
692/4020/4021
692/699/1503/1607/1605
Administration
Administration, Oral
Aged
Antiviral Agents
Antiviral Agents - administration & dosage
Antiviral Agents - adverse effects
Antiviral drugs
Carbamates
Carbamates - administration & dosage
Carcinoma
Carcinoma, Hepatocellular
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - prevention & control
Carcinoma, Hepatocellular - virology
Chronic / diagnosis
Chronic / drug therapy
Chronic / epidemiology
Chronic / virology
Clinical trials
Combination
Drug Therapy
Drug Therapy, Combination
Elasticity Imaging Techniques
Eradication
Female
Fibrosis
Hepatitis C
Hepatitis C, Chronic
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - epidemiology
Hepatitis C, Chronic - virology
Hepatocellular / diagnosis
Hepatocellular / epidemiology
Hepatocellular / prevention & control
Hepatocellular / virology
Hepatocellular carcinoma
Humanities and Social Sciences
Humans
Imidazoles
Imidazoles - administration & dosage
Incidence
Interferon
Interferons
Interferons - administration & dosage
Isoquinolines
Isoquinolines - administration & dosage
Liver
Liver cancer
Liver Cirrhosis
Liver Cirrhosis - diagnostic imaging
Liver Cirrhosis - drug therapy
Liver Cirrhosis - epidemiology
Liver Cirrhosis - virology
Liver Neoplasms
Liver Neoplasms - diagnosis
Liver Neoplasms - epidemiology
Liver Neoplasms - prevention & control
Liver Neoplasms - virology
Male
Medicine
Middle Aged
multidisciplinary
Oral
Patients
Prospective Studies
Pyrrolidines
Pyrrolidines - administration & dosage
Q
R
Retrospective Studies
Ribavirin
Ribavirin - administration & dosage
Science
Science (multidisciplinary)
Seoul
Sulfonamides
Sulfonamides - administration & dosage
Sustained Virologic Response
Time Factors
Treatment Outcome
Valine
Valine - administration & dosage
Valine - analogs & derivatives
Seoul
ISSN:2045-2322, 2045-2322
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p  < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-03272-1